Will Pfizer’s Lyme disease gamble pay off or set the space back?

As the disease spreads into new regions, the urgency for prevention is growing.

By Kelly Bilodeau • April 1, 2026

mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts

Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.

By Alexandra Pecci • March 31, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Big Pharma goes nuts over food allergies — again

Novartis’ acquisition of Excellergy for up to $2 billion portends a potential new wave of medicines for food allergies.

By Michael Gibney • March 31, 2026

Can Ocugen succeed where other gene therapy makers have struggled?

The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.

By Meagan Parrish • March 27, 2026

Novo’s FDA voucher victory; biotech’s rigid glass ceiling

While Novo Nordisk collected a win through the FDA’s new voucher program, the initiative remains unpredictable and controversial.

By PharmaVoice Staff • March 27, 2026

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.

By Jacob Bell • March 26, 2026

Mixed signals cloud the orphan drug market

The field is making gains despite regulatory inconsistency, but rising competition from obesity candidates and evolving global pressures could erode orphan drugs’ market share.

By Kelly Bilodeau • March 25, 2026

Women in biotech hit a leadership plateau as board barriers persist

A new initiative from BioIndustry Association and AstraZeneca aims to boost representation on heavily dominated male boards.

By Alexandra Pecci • March 24, 2026

How AI is reshaping clinical trials

Human oversight remains crucial as the technology is leveraged in safety monitoring, boosting clinical trial diversity and more.

By Kelly Bilodeau • March 23, 2026

Lilly’s manufacturing bet; hints of a biotech revival

Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.

By PharmaVoice Staff • March 20, 2026

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.

By Alexandra Pecci • March 19, 2026

As Chinese biotechs recognize their value, the bargain era may be over

Rising average upfront payments signal that buyers see value in Chinese assets.

By Kelly Bilodeau • March 18, 2026

VC sees early signs of a biotech market spring as long winter fades

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.

By Michael Gibney • March 17, 2026

Keytruda’s reign continues; pharma’s megadeal drought

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our radar this week.

By PharmaVoice Staff • March 13, 2026

Executives want in, but researchers want out — how pharma’s US job picture is changing

While academics are eyeing friendlier work opportunities abroad, America’s manufacturing boom is drawing industry leaders to its shores.

By Alexandra Pecci • March 10, 2026

Servier’s $2.5B cancer bet underlines a quick oncology growth strategy

Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it pumps up its pipeline.

By Michael Gibney • March 10, 2026

The first KRAS drugs have been sluggish on the market. Will the next generation fare better?

The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

By Kelly Bilodeau • March 9, 2026

Biopharma’s recent string of CEO splits

Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.

By Meagan Parrish • March 6, 2026

What 3 recent FDA rejections reveal about shifts inside the agency

The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.

By Alexandra Pecci • March 4, 2026

Big Pharma’s next entrant could come from China

Companies with a growing international presence like Jiangsu Hengrui Pharmaceuticals are on their way to joining the big leagues.

By Kelly Bilodeau • March 2, 2026

Biohaven says FDA roadblocks leave rare disease patients in limbo

An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.

By Michael Gibney • Feb. 26, 2026

China’s biopharma advance draws financial investment

Experts are still keeping a close eye on geopolitical uncertainties, but licensing deals are turning into monetary growth.

By Kelly Bilodeau • Feb. 25, 2026

Will the FDA yank mRNA vaccines?

Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.

By Alexandra Pecci • Feb. 24, 2026

How does the FDA really feel about psychedelics? We could soon find out.

Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.

By Kelly Bilodeau • Feb. 23, 2026

Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.

By Michael Gibney • Feb. 19, 2026